Eicosanoids in bovine retinal microcirculation.
The vasoactive effects of the arachidonic acid-derived cyclooxygenase product, prostaglandin F2 alpha and PGH2 analogue U46619, on ex vivo perfused (25 microliters/min) bovine retinal microcirculation were assessed. First, we determined the ability of the cultured bovine retinal microvascular endothelial cells to synthesize eicosanoids from 14C-arachidonic acid. Bovine retinal microvascular endothelial cell cultures synthesized detectable amounts of PGE2, PGF2 alpha, PGI2, and PGH2 analogue; PGI2 product being slightly greater. The central retinal arteriole was cannulated and microcirculation continuously perfused with PSS with constant flow. Vasoactive compounds were applied in ten-fold concentration increments to PSS in the muscle chamber containing retinal preparation. The diameters of retinal microarterioles were measured using a closed-circuit video camera system. In ex vivo bovine retinal microvascular model studies, PGF2 alpha and PGH2 analogue U46619, caused dose-dependent vasoconstriction of all vessels, and these responses were attenuated by specific TP (TXA2) receptor antagonist, SQ 29,548, at 10(-6) M.
Kulkarni
P
P
University of Louisville School of Medicine, Department of Ophthalmology and Visual Sciences, Kentucky, USA.
Payne
S
S
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001160:Arterioles / Q000187:drug effects / Q000502:physiology; D002250:Carbon Radioisotopes; D002417:Cattle; D002478:Cells, Cultured; D015237:Dinoprost / Q000096:biosynthesis / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D004727:Endothelium / Q000166:cytology / Q000378:metabolism; D066298:In Vitro Techniques; D008833:Microcirculation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology*; D011849:Radioactive Tracers; D012161:Retinal Artery / Q000187:drug effects / Q000502:physiology*; D013928:Thromboxane A2 / Q000031:analogs & derivatives* / Q000494:pharmacology; D013929:Thromboxane B2 / Q000096:biosynthesis; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D002250:Carbon Radioisotopes; D011450:Prostaglandin Endoperoxides, Synthetic; D011849:Radioactive Tracers; D014662:Vasoconstrictor Agents; D016718:Arachidonic Acid; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015237:Dinoprost; D015232:Dinoprostone